Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : $1,125.0 million
Deal Type : Acquisition
Japan's Otsuka Pharma to pay up to $1.1 bln to acquire Jnana Therapeutics
Details : Through the acquisition, Otsuka will leverage Jana pipelines, which include JNT-517 an allosteric small molecule inhibitor of SLC6A19. It is being evaluated for the treatment of phenylketonuria.
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : $800.0 million
August 01, 2024
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Otsuka Pharmaceutical
Deal Size : $1,125.0 million
Deal Type : Acquisition
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNT-517 is a, oral small-molecule, phenylalanine (Phe) transporter SLC6A19 inhibitor, a potential therapy used to treat PKU, regardless of age or genotype. JNT-517 acts at a novel, cryptic allosteric site...
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Not Applicable
January 06, 2023
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bain Capital Life Sciences
Deal Size : $107.0 million
Deal Type : Series C Financing
Details : The proceeds from the funding will be used to progress the company’s lead program JNT-517 in phenylketonuria (PKU), a rare genetic metabolic disease, through a clinical proof-of-concept (POC) study, and...
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Undisclosed
November 15, 2022
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Bain Capital Life Sciences
Deal Size : $107.0 million
Deal Type : Series C Financing
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : JNT-517, is a small molecule, allosteric inhibitor of SLC6A19, a metabolite transporter responsible for reabsorption of phenylalanine (Phe) in the kidney.
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Not Applicable
July 08, 2022
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Discovery of JNT-517, which targets SLC6A19, is based on Jnana’s pioneering research and was enabled by RAPID, company’s high-throughput screening-enabled chemoproteomic platform for treatment of PKU ...
Product Name : JNT-517
Product Type : Small molecule
Upfront Cash : Not Applicable
February 23, 2022
Lead Product(s) : JNT-517
Therapeutic Area : Genetic Disease
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?